Retatrutide: Triple Hormone Receptor Agonist

Retatrutide is an investigational peptide being studied as a triple hormone receptor agonist, activating GLP-1, GIP and glucagon receptors simultaneously. It holds no marketing authorisation in the UK or elsewhere and is available only within an authorised clinical trial. This article outlines what retatrutide is, what clinical trials have reported, its current regulatory status in the UK, and the safety signals identified so far, drawing on published trial data and UK regulatory frameworks.

What is retatrutide and how does it work as a triple hormone receptor agonist?

Retatrutide is an investigational peptide that activates GLP-1, GIP and glucagon receptors simultaneously, with each pathway hypothesised to contribute distinct effects on appetite, insulin secretion and energy expenditure. It is not authorised in the UK and is available only within an authorised clinical trial.

Retatrutide is an investigational peptide that simultaneously activates three hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors, making it a triple agonist under active clinical investigation. It is not authorised in the UK or anywhere else, and it is available only within an authorised clinical trial.

Each of the three receptor pathways is hypothesised to contribute a distinct mechanism. GLP-1 receptor activation slows gastric emptying, reduces appetite and supports insulin secretion in a glucose-dependent manner.^[12][20] GIP receptor activation further modulates insulin release and may enhance the metabolic effects of GLP-1 signalling.^[22][21] Glucagon receptor activation is hypothesised to increase energy expenditure and promote fat breakdown in the liver; the clinical significance of this glucagon component in humans continues to be evaluated in ongoing trials.^[23][24] These mechanisms are not shared by the dual GLP-1 and GIP agonist tirzepatide (Mounjaro) or the GLP-1 agonists semaglutide (Wegovy, Ozempic) and liraglutide (Saxenda), all of which are separately authorised medicines.^[10][11]

By engaging all three pathways together, retatrutide is designed to address appetite regulation, insulin sensitivity and energy expenditure through complementary routes. Whether this combination produces additive metabolic effects of clinical significance remains under evaluation in ongoing trials. The peptide is administered by subcutaneous injection, and its pharmacological profile is being characterised across a range of dose levels within the trial programme.

What have clinical trials reported about retatrutide and weight loss?

The Phase 2 trial reported a mean body weight reduction of approximately 24 per cent at 48 weeks at the highest dose; Phase 3 TRIUMPH and TRANSCEND trials are ongoing and will provide broader efficacy and safety data. Trial results cannot be generalised to the wider population.

Clinical trials of retatrutide have reported substantial reductions in body weight in participants with obesity, though all findings must be interpreted within the context of controlled trial settings and cannot be generalised to the broader population. The Phase 2 trial, published in the New England Journal of Medicine in 2023, enrolled adults with obesity or overweight and reported that participants receiving the highest dose achieved a mean body weight reduction of approximately 17 per cent at 24 weeks and around 24 per cent at 48 weeks, compared with placebo.^[1][3] These figures reflect trial outcomes in a specific population under protocol conditions.

The Phase 3 programme, which includes the TRIUMPH and TRANSCEND trial series, is evaluating retatrutide across broader populations, including people with type 2 diabetes and those with obesity-related cardiovascular risk.^[4][5] Phase 3 readouts have begun to emerge: results from the TRANSCEND-T2D-1 trial have been reported, and data from the TRIUMPH programme have been presented at major diabetes and obesity congresses.^[4][5] These larger, longer trials are designed to assess both efficacy and safety with greater statistical power and across more diverse groups than the Phase 2 data permitted. The evidence base continues to evolve as further findings from the TRIUMPH and TRANSCEND programmes are published.

It is important to note that trial results are not a prediction of what any individual would experience. Participants in clinical trials are selected according to strict eligibility criteria, follow closely monitored protocols, and receive intensive support that differs from routine clinical care. Cross-trial numeric comparisons are unreliable because no head-to-head trials between retatrutide and currently licensed medicines have been conducted.

What is the current regulatory status of retatrutide in the UK?

Retatrutide has no MHRA marketing authorisation and has not entered NICE evaluation; it is available only within an authorised clinical trial, and no other legal route of supply exists in the UK.

Retatrutide holds no marketing authorisation in the UK, and no authorisation date can be given. It is available only within an authorised clinical trial, and no other route of supply exists. Anyone offering retatrutide outside a clinical trial setting is not supplying a licensed product, and any product sold online under this name may be falsified and potentially dangerous.

In the UK, medicines are authorised by the Medicines and Healthcare products Regulatory Agency (MHRA).^[13][14] Authorisation requires the submission of a complete dossier of quality, safety and efficacy data, followed by a rigorous scientific assessment. Even after MHRA authorisation, a separate process determines NHS availability: the National Institute for Health and Care Excellence (NICE) evaluates clinical and cost-effectiveness before making recommendations, and local Integrated Care Boards (ICBs) make commissioning decisions within their areas.^[15][16] Retatrutide has not entered any of these stages in the UK.

For people interested in participating in clinical research, the NIHR's Be Part of Research service (bepartofresearch.nihr.ac.uk) is the authoritative UK patient-facing resource for finding and joining clinical trials. The Health Research Authority (HRA) also publishes summaries of approved studies. Participation is subject to eligibility criteria set by each trial protocol. People who are interested in currently licensed weight-management treatments can discuss their options with their GP, who can advise on what is available and appropriate for their individual circumstances.

What side effects and safety signals have trials identified so far?

Phase 2 trials identified dose-dependent gastrointestinal effects and heart rate increases as the most notable signals; pancreatitis and gallbladder disease are class-related areas under monitoring in ongoing Phase 3 trials.

The Phase 2 trial of retatrutide identified a side-effect profile broadly consistent with other medicines in the GLP-1 receptor agonist class, with gastrointestinal effects being the most commonly reported. These included nausea, vomiting, diarrhoea and constipation, which were generally dose-dependent and most frequent during dose escalation. Most gastrointestinal events were described as mild to moderate in severity.

Heart rate increases were observed in participants receiving retatrutide, a finding that has also been noted with other agents in this class and which is being monitored carefully in the Phase 3 TRIUMPH and TRANSCEND programmes.^[18][17] The clinical significance of this finding in the longer term is not yet fully established. As with other GLP-1 receptor agonist class medicines, pancreatitis and gallbladder disease have been identified as class-related areas under monitoring; participants with a history of pancreatitis are typically excluded from trials.^[6] Because retatrutide is investigational, its full safety profile has not been characterised, and these class signals should not be taken as established retatrutide-specific risks.

Participants enrolled in a retatrutide trial should carry their trial participant card or identification at all times and inform any emergency or unscheduled care team that they are taking part in a clinical trial. This allows healthcare professionals to access relevant trial information promptly. Any adverse events should be reported to the trial team in accordance with the study protocol. Suspected side effects from medicines can also be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk; however, if you are enrolled in a clinical trial, your primary reporting route is the trial team or sponsor.

Retatrutide trials exclude participants who are pregnant, breastfeeding or planning a pregnancy, reflecting the precautionary approach standard for investigational medicines in this class. Women of childbearing potential enrolled in trials are required to use effective contraception throughout participation. Anyone with questions about safety signals or trial eligibility should speak to their GP or the relevant trial team.

Frequently Asked Questions